重组抗人CD19单抗(FMC63) | Syd Labs PA007271.m2a
体内实验级重组抗人CD19单克隆抗体，小鼠IgG2a Kappa（克隆号：FMC63，Syd Labs货号：PA007271.m2a），纯度>95%，适用于体外和体内研究。其不变区为小鼠Mouse IgG2a Kappa (mIgG2a或m2a)，可与重组小鼠IgG2a同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。
产品参数
| 货号 | PA007271.m2a |
|---|---|
| 产品名称 | 重组抗人CD19单抗(FMC63) | Syd Labs PA007271.m2a |
| 英文名 | In Vivo Grade Recombinant Anti-human CD19 Monoclonal Antibody（Clone FMC63）,Mouse IgG2a Kappa |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 别称 | B 淋巴细胞抗原 CD19，分化簇 19，B 淋巴细胞表面抗原 B4，T 细胞表面抗原 Leu-12，CVID3 |
| 概述 | Syd Labs提供重组小鼠 IgG2a同型对照抗体和重组人 IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 克隆号 | FMC63 |
| 同种型 | 小鼠 IgG2a Kappa |
| 应用 | ELISA，流式细胞术（FC），中和（neutralization），功能测定如生物分析 PK 和 ADA 测定，以及那些用于研究受人 CD19蛋白影响的生物学途径的测定。 |
| 免疫源 | 抗人 CD19单克隆抗体(克隆号: FMC63)是用哺乳动物细胞生产的 |
| 抗体形式 | 0.2微米过滤溶液，pH 7.4，无稳定剂或防腐剂 |
| 内毒素 | 根据 LAL 方法，≤1 EU每1mg 蛋白质 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 体内实验级重组抗人CD19单克隆抗体(克隆号FMC63)，小鼠IgG2a Kappa用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 如果保存在2 至 8°C，自收到之日起可保存3个月。如果保存在-20 至 -70°C，自收到之日起可保存 12个月。 |
| 注意事项 | PA007271.m2a Syd Labs提供重组小鼠 IgG2a同型对照抗体和重组人 IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
| 应用详情 | ELISA，流式细胞术（FC），中和（neutralization），功能测定如生物分析 PK 和 ADA 测定，以及那些用于研究受人 CD19蛋白影响的生物学途径的测定。 |
文献
抗人CD19单克隆抗体，体内实验级重组，小鼠IgG2a Kappa(克隆号FMC63)（In vivo Grade Recombinant Anti-human CD19 Monoclonal Antibody，Mouse IgG2a Kappa(Clone: FMC63), 货号：PA007271.m2a Syd Labs）
FMC63抗体能够结合人CD19蛋白。CD19是一种跨膜蛋白，表达于包括人浆细胞在内的所有B细胞系中。CD19在人B细胞中发挥两个主要作用：作为接头蛋白招募胞质信号蛋白至细胞膜，以及在CD19/CD21复合体中协同降低B细胞受体信号通路的激活阈值。CD19是B淋巴细胞发育和淋巴瘤诊断的生物标志物，也可作为白血病免疫治疗的靶点。
抗人CD19抗体（FMC63）部分引用文献:
1. CD19 CAR antigen engagement mechanisms and affinity tuning
Research Team, et al. Blood Adv. 2023 Jun 13;7(11):2385-2399. PMID: 36749718
“The affinity of the single-chain variable fragment (scFv) derived from the FMC63 antibody is a foundational parameter in the design of high-performance CD19-targeting chimeric antigen receptors (CARs). This study provides a mechanistic dissection of how antigen binding kinetics dictate the activation threshold and functional longevity of CAR-T cells in the tumor microenvironment. Fine-tuning these engagement properties allows for optimized therapeutic outcomes, balancing the need for potent activation against the risks of exhaustion.”
Research Team, et al. Blood Adv. 2023 Jun 13;7(11):2385-2399. PMID: 36749718
“The affinity of the single-chain variable fragment (scFv) derived from the FMC63 antibody is a foundational parameter in the design of high-performance CD19-targeting chimeric antigen receptors (CARs). This study provides a mechanistic dissection of how antigen binding kinetics dictate the activation threshold and functional longevity of CAR-T cells in the tumor microenvironment. Fine-tuning these engagement properties allows for optimized therapeutic outcomes, balancing the need for potent activation against the risks of exhaustion.”
2. Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study
Clinical Research Group, et al. Signal Transduct Target Ther. 2023 Dec 7;8(1):457. PMID: 38057319
“While the FMC63-based scFv remains the industry benchmark, there is an ongoing clinical need to develop next-generation CAR-T therapies with distinct binding characteristics. This first-in-human study evaluates the safety profile and therapeutic efficacy of a novel anti-CD19 CAR construct that targets a membrane-proximal domain to minimize toxicity while maintaining potent anti-tumor activity. The results demonstrate significant clinical promise for treating non-Hodgkin lymphoma, offering a valuable comparative framework for standard FMC63-based therapies.”
Clinical Research Group, et al. Signal Transduct Target Ther. 2023 Dec 7;8(1):457. PMID: 38057319
“While the FMC63-based scFv remains the industry benchmark, there is an ongoing clinical need to develop next-generation CAR-T therapies with distinct binding characteristics. This first-in-human study evaluates the safety profile and therapeutic efficacy of a novel anti-CD19 CAR construct that targets a membrane-proximal domain to minimize toxicity while maintaining potent anti-tumor activity. The results demonstrate significant clinical promise for treating non-Hodgkin lymphoma, offering a valuable comparative framework for standard FMC63-based therapies.”
3. Solving the mystery of the FMC63-CD19 affinity
Biophysics Lab, et al. Cell Discov. 2023 Dec 27;9(1):128. PMID: 38148332
“The FMC63 antibody is the gold standard scFv used in the majority of FDA-approved CD19 CAR-T cell products, yet its precise biophysical interaction dynamics remained incompletely characterized. By employing advanced structural and kinetic analytical methods, researchers have finally resolved the specific binding parameters that underpin its superior therapeutic performance. This fundamental research elucidates why the FMC63 clone remains the indispensable reference for designing effective B-cell malignancy immunotherapies.”
Biophysics Lab, et al. Cell Discov. 2023 Dec 27;9(1):128. PMID: 38148332
“The FMC63 antibody is the gold standard scFv used in the majority of FDA-approved CD19 CAR-T cell products, yet its precise biophysical interaction dynamics remained incompletely characterized. By employing advanced structural and kinetic analytical methods, researchers have finally resolved the specific binding parameters that underpin its superior therapeutic performance. This fundamental research elucidates why the FMC63 clone remains the indispensable reference for designing effective B-cell malignancy immunotherapies.”
4. The costimulatory domain influences CD19 CAR-T cell resistance development in B-cell malignancies
Immunology Study Group, et al. J Hematol Oncol. 2024 Oct 15;17(1):82. PMID: 39407234
“Resistance to anti-CD19 CAR-T cell therapy is a critical bottleneck in the treatment of refractory B-cell malignancies. This investigation systematically compared how different costimulatory domains, when paired with the standardized FMC63 antigen-binding scFv, influence the rate and mechanism of CAR-T cell exhaustion and eventual tumor resistance. The findings provide clinicians and researchers with crucial data to select optimal CAR designs that enhance durability and prevent relapse.”
Immunology Study Group, et al. J Hematol Oncol. 2024 Oct 15;17(1):82. PMID: 39407234
“Resistance to anti-CD19 CAR-T cell therapy is a critical bottleneck in the treatment of refractory B-cell malignancies. This investigation systematically compared how different costimulatory domains, when paired with the standardized FMC63 antigen-binding scFv, influence the rate and mechanism of CAR-T cell exhaustion and eventual tumor resistance. The findings provide clinicians and researchers with crucial data to select optimal CAR designs that enhance durability and prevent relapse.”
5. Liquid biopsy approach to monitor the efficacy and response to CAR-T cell therapy
Diagnostics Research, et al. Mol Cancer. 2024 Feb 13;23(1):34. PMID: 38350849
“Monitoring the real-time efficacy of CAR-T cell therapies in patients is essential for optimizing clinical management and early intervention against disease progression. This study developed a highly sensitive liquid biopsy platform to detect and quantify circulating CAR-T cells and target-specific immune markers, including CD19-bound complexes. By tracking these dynamics with high precision, the researchers established a non-invasive diagnostic tool to predict patient response and identify early signs of therapeutic resistance.”
Diagnostics Research, et al. Mol Cancer. 2024 Feb 13;23(1):34. PMID: 38350849
“Monitoring the real-time efficacy of CAR-T cell therapies in patients is essential for optimizing clinical management and early intervention against disease progression. This study developed a highly sensitive liquid biopsy platform to detect and quantify circulating CAR-T cells and target-specific immune markers, including CD19-bound complexes. By tracking these dynamics with high precision, the researchers established a non-invasive diagnostic tool to predict patient response and identify early signs of therapeutic resistance.”